370
Participants
Start Date
October 22, 2020
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
Dabigatran etexilate
Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
Warfarin
Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
RECRUITING
The University of Hong Kong / Queen Mary Hospital, Hong Kong
The University of Hong Kong
OTHER